First human trial of PRL3-ZUMAB aims to find safe dose for advanced cancers
NCT ID NCT03191682
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study tests the safety of a new drug, PRL3-ZUMAB, in people with advanced solid tumors that have not responded to standard treatments. It is the first time this drug is given to humans, after showing good tolerance in animals. The main goal is to find the safest dose and check for side effects. About 38 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore, 119.074, Singapore
Conditions
Explore the condition pages connected to this study.